newsfilter
← Earnings
Earnings Releases·

Mentari Therapeutics, Inc. — Nine Months Ended September 30, 2026 Earnings Summary

Mentari Therapeutics, Inc. reported a net loss of $63.0 million for the nine months ended September 30, 2026, driven primarily by $57.7 million in research and development expenses. The company maintained $45.8 million in cash and cash equivalents as of September 30, 2026, while holding significant liabilities including a $50.0 million convertible note payable to a related party. On November 6, 2026, the company completed a merger with InMed Pharmaceuticals, resulting in a combined entity focused on migraine prevention therapies. This transaction was preceded by a $490.0 million pre-closing financing that provided additional capital for the company's development programs.

Company
MENTARI THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology